Incidentalome from Genomic Sequencing: A Barrier to Personalized Medicine?
- PMID: 27077130
- PMCID: PMC4816806
- DOI: 10.1016/j.ebiom.2016.01.030
Incidentalome from Genomic Sequencing: A Barrier to Personalized Medicine?
Abstract
Background: In Western cohorts, the prevalence of incidental findings (IFs) or incidentalome, referring to variants in genes that are unrelated to the patient's primary condition, is between 0.86% and 8.8%. However, data on prevalence and type of IFs in Asian population is lacking.
Methods: In 2 cohorts of individuals with genomic sequencing performed in Singapore (total n = 377), we extracted and annotated variants in the 56 ACMG-recommended genes and filtered these variants based on the level of pathogenicity. We then analyzed the precise distribution of IFs, class of genes, related medical conditions, and potential clinical impact.
Results: We found a total of 41,607 variants in the 56 genes in our cohort of 377 individuals. After filtering for rare and coding variants, we identified 14 potential variants. After reviewing primary literature, only 4 out of the 14 variants were classified to be pathogenic, while an additional two variants were classified as likely pathogenic. Overall, the cumulative prevalence of IFs (pathogenic and likely pathogenic variants) in our cohort was 1.6%.
Conclusion: The cumulative prevalence of IFs through genomic sequencing is low and the incidentalome may not be a significant barrier to implementation of genomics for personalized medicine.
Keywords: Genomic sequencing; Incidental findings; Personalized medicine.
Similar articles
-
Next-generation sequencing using a pre-designed gene panel for the molecular diagnosis of congenital disorders in pediatric patients.Hum Genomics. 2015 Dec 14;9:33. doi: 10.1186/s40246-015-0055-x. Hum Genomics. 2015. PMID: 26666243 Free PMC article.
-
Identification of Medically Actionable Secondary Findings in the 1000 Genomes.PLoS One. 2015 Sep 2;10(9):e0135193. doi: 10.1371/journal.pone.0135193. eCollection 2015. PLoS One. 2015. PMID: 26332594 Free PMC article.
-
Attitudes of nearly 7000 health professionals, genomic researchers and publics toward the return of incidental results from sequencing research.Eur J Hum Genet. 2016 Jan;24(1):21-9. doi: 10.1038/ejhg.2015.58. Epub 2015 Apr 29. Eur J Hum Genet. 2016. PMID: 25920556 Free PMC article.
-
Next generation sequencing: implications in personalized medicine and pharmacogenomics.Mol Biosyst. 2016 May 24;12(6):1818-30. doi: 10.1039/c6mb00115g. Mol Biosyst. 2016. PMID: 27066891 Review.
-
Gene and Variant Annotation for Mendelian Disorders in the Era of Advanced Sequencing Technologies.Annu Rev Genomics Hum Genet. 2017 Aug 31;18:229-256. doi: 10.1146/annurev-genom-083115-022545. Epub 2017 Apr 17. Annu Rev Genomics Hum Genet. 2017. PMID: 28415856 Review.
Cited by
-
Implementation of genomics in medical practice to deliver precision medicine for an Asian population.NPJ Genom Med. 2019 Jun 7;4:12. doi: 10.1038/s41525-019-0085-8. eCollection 2019. NPJ Genom Med. 2019. PMID: 31231544 Free PMC article. Review.
-
Population genomics in South East Asia captures unexpectedly high carrier frequency for treatable inherited disorders.Genet Med. 2019 Jan;21(1):207-212. doi: 10.1038/s41436-018-0008-6. Epub 2018 Jul 2. Genet Med. 2019. PMID: 29961769
-
Novel Pathogenic Germline Variant of the Adenomatous Polyposis Coli (APC) Gene, p.S2627Gfs*12 Identified in a Mild Phenotype of APC-Associated Polyposis: A Case Report.Am J Case Rep. 2020 Dec 11;21:e927293. doi: 10.12659/AJCR.927293. Am J Case Rep. 2020. PMID: 33303731 Free PMC article.
-
Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.OMICS. 2017 Mar;21(3):123-131. doi: 10.1089/omi.2017.0006. Epub 2017 Feb 16. OMICS. 2017. PMID: 28253087 Free PMC article.
-
Actionable secondary findings from whole-genome sequencing of 954 East Asians.Hum Genet. 2018 Jan;137(1):31-37. doi: 10.1007/s00439-017-1852-1. Epub 2017 Nov 11. Hum Genet. 2018. PMID: 29128982
References
-
- Ayuso C., Millan J.M., Dal-Re R. Management and return of incidental genomic findings in clinical trials. Pharmacogenomics J. 2015;15(1):1–5. - PubMed
-
- Ballinger M.L., Mitchell G., Thomas D.M. Surveillance recommendations for patients with germline TP53 mutations. Curr. Opin. Oncol. 2015;27(4):332–337. - PubMed
-
- Berg J.S., Khoury M.J., Evans J.P. Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet. Med. 2011;13(6):499–504. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources